Perioperative Tislelizumab Plus Neoadjuvant Chemotherapy in the Treatment of Patients With Resectable Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Lancet Respir Med 2024 Nov 21;[EPub Ahead of Print], D Yue, W Wang, H Liu, Q Chen, C Chen, L Liu, P Zhang, G Zhao, F Yang, G Han, Y Cheng, B Yu, Y Yang, H Chen, J Jiang, L Tan, S Xu, N Mao, J Hu, L Zhang, B Yao, S Wang, RH Wang, W Zheng, C WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.